期刊
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
卷 5, 期 3, 页码 172-187出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157489210791760526
关键词
Anti-cancer drug; alkylating drug; DNA damage; temozolomide; triazenes
资金
- Ministero Italiano dell'Universita e della Ricerca
- RSA Tor Vergata
Temozolomide (TMZ) is a monofunctional methylating agent which is spontaneously activated in aqueous solution into the dacarbazine metabolite 5-(3-methyl-1-triazeno)imidazole-4-carboxamide. This drug has been approved for the treatment of metastatic melanoma and glioblastoma multiforme, the latter in combination with radiotherapy. Furthermore, clinical trials have been performed to assess the activity of TMZ, alone or in combination, on brain metastatic solid tumors and leukaemias. This review will report clinical evidence on the use of TMZ for the treatment of different types of cancer; it also considers current knowledge on TMZ's molecular mechanisms of action of and discusses relevant patents relating to the same drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据